fig4

Figure 4. Ivosidenib increases the sensitivity of SKDDP and SK-3rd to cisplatin. (A) Dose-response curves of SKDDP and SK-3rd detected by MTT assay treated with cisplatin and 0 μM, 1 μM, 5 μM, 10 μM, 20 μM, and 50 μM Ivosidenib for 72 h. Data represent mean ± SD of three biologically independent experiments. (B) The lC₅₀ of SKDDP and SK-3rd to cisplatin in (A). Data represent mean ± SD of three biologically independent experiments. ns, not significant, *P <0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 using a one-way ANOVA followed by Tukey's post hoc test for multiple comparisons. (C) Fa-CI plot of combined treatments of cisplatin (0.5 μM, 5 μM, 10 μM, 20 μM, 50 μM, 100 μM) and Ivosidenib (5 μM, 10 μM) of SKDDP, and SK-3rd cells. The combination index was calculated using CompuSyn software. CI < 1, =1, and >1 indicate synergistic, additive, and antagonistic effects, respectively. CI, Combination index. Fa, Fraction affected. Each score represents data from three biologically independent experiments. (D) CI scores of SKDDP and SK-3rd cells treated with Ivosidenib in combination with cisplatin at the indicated concentrations. Each CI score represents data from three biologically independent experiments. (E) Quantification of cell colony number in SKDDP and SK-3rd cells treated with Ivosidenib, cisplatin, or their combination for 72 h. Data represent mean ± SD of three biologically independent experiments. ns, not significant, *P <0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 using a two-way ANOVA followed by Tukey's post hoc test for multiple comparisons. (F) Quantification of cell apoptosis analysis in SKDDP and SK-3rd cells treated with DMSO, 10 μM Ivosidenib, 10 μM cisplatin, or their combination for 72 h. Annexin V-positive cells were analyzed by flow cytometry after treatment. Data represent mean ± SD of three biologically independent experiments. ns, not significant, ***P < 0.001; ****P < 0.0001 using a one-way ANOVA followed by Tukey's post hoc test for multiple comparisons.